Common Inherited Bleeding Disorders

Size: px
Start display at page:

Download "Common Inherited Bleeding Disorders"

Transcription

1 CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also in circulation Injury to the blood vessel Contact with tissue factor and other subendothelial tissues 1

2 CAA 2015 Annual Conference Bleeding at site of injury with exposure to subendothelium with platelet activation VIII VWF tethers to exposed endothelium at site of injury VIII p vwf VIII Shear vwf vwf latelets are activated and adhere to VWF and then aggregate to form platelet plug VIII VIII vwf vfw vwf 2

3 CAA 2015 Annual Conference Activated coagulation proteins form fibrin strands VIII V IX VII X XIII I vwf vwf vwf II Fibrin Strands Fibrin Clot 3

4 CAA 2015 Annual Conference vwd Glanzmann s Thrombasthenia Bernard Soulier Syndrome G IIb/III a Fibrinogen Afibrinogenemia A representation of normal platelet responses and the congenital disorders of platelet function Deficiency of latelet Coagulant Activities Reproduced with permission from: Rao AK. Am J Med Sci. 1998;316:

5 CAA 2015 Annual Conference etechiae eter Maslak, ASH Image Bank 2011; Copyright 2011 American Societyof Hematology. Copyrightrestrictionsmay apply. atterns of Bleeding latelet type Coagulation type... mucous membrane epistaxis petechiae menorrhagia bruising soft tissue muscles joints latelet Function Evaluation IVY bleeding time lt Aggregation to : AD Epinephrine Collagen Ristocetin Arachidonic acid FA - latelet function analyzer 5

6 CAA 2015 Annual Conference Inherited Disorders Affecting latelets Low von Willebrand factor protein (common) von Willebrands Disease (VWD) Function defects in the platelet (rare) Glannsman s thrombasthenia Bernard-Soulier syndrome Vessel wall abnormalities (rare) Connective tissue disorders vwd Glanzmann s Thrombasthenia Bernard Soulier Syndrome G IIb/III a Fibrinogen Afibrinogenemia A representation of normal platelet responses and the congenital disorders of platelet function Deficiency of latelet Coagulant Activities Reproduced with permission from: Rao AK. Am J Med Sci. 1998;316: VWD.bleeding VWD Mucous membranes Epistaxis Menorrhagia Superficial (petechiae) Hemophilia Deep bruising Joints Muscles 6

7 CAA 2015 Annual Conference von Willebrand Disease Estimated 1% of population (autosomal) Type 1 mild / most common Type 2 mild to moderate Type 3 severe von Willebrand Disease Type 1 Reduced quantity of VWF VWF normal, just reduced Mild and most common ~ 80% of all VWD VWD.diagnosis FVIII VWF:Ag RCof Type 1 All three partially decreased to similar levels 7

8 CAA 2015 Annual Conference Basic Bleeding Work-up CBC w/ platelet ct NL T 11.2 (10-12) TT 46 (31-43) Extra coag tube FVIII 38 (50-150) VWF Antigen 42 (50-150) Ristocetin (R cof.) 35 (50-150) Basic Bleeding Work-up CBC w/ platelet ct NL T 10.9 (10-12) TT 46 (31-43) Extra coag tube FVIII 32 (50-150) VWF Antigen 12 (50-150) Ristocetin (R cof.) 0 (50-150) von Willebrand Disease Type 2 Qualitative defects in function Type 2A Lacks HMW multimers Type 2B Gain of function Increased platelet binding = low plt ct 8

9 CAA 2015 Annual Conference von Willebrand Disease Type 2 Qualitative defects in function Type 2M Decreased binding to G1 Type 2N (Normandy) Normal amount of VWF (Ag & Rcof normal) Decreased binding to FVIII = low FVIII? Misdiagnosed as hemophilia A A Short Case # 1 MR is a 10 y/o Caucasian male scheduled for a tonsillectomy HX of excess bleeding beginning several hours after recent tooth extraction. Epistaxis has been rare and of short duration. Some minor bruising in the past usually after sports. No recent medications. Case #1 Initial Lab Values re-op lab values revealed: rolonged TT = 45 sec (24-38) Normal T = 11.5 sec (10-13) CBC normal except for a plt ct of 95,000 9

10 CAA 2015 Annual Conference Case #1 Lab Workup rolonged TT? Factor VIII level = 36% (50-150) Low platelet ct? VWD type 2B? VWF Ag = 38% (50-150) Rcof = 11% (50-150) Further confirming workup RIA increased Multimers = loss of HMW VWF Multimers von Willebrand Disease Type 3 VWF very low or absent Severe clinical features 10

11 CAA 2015 Annual Conference Basic Bleeding Work-up CBC w/ platelet ct NL T 11.0 (10-12) TT, 1:1 mix 59 (31-43) Extra coag tube FVIII 3 (50-150) VWF Antigen <12 (50-150) Ristocetin R cof. <6 (50-150) VWD... lab tests VIII VWF:Ag RCof Bleeding time VWF multimers Blood group RIA latelet count von Willebrand Disease Diagnosis Repeated testing may be needed Bleeding history important Family history / inheritance Autosomal dominant / recessive 11

12 CAA 2015 Annual Conference Basic Bleeding Work-up CBC w/ platelet ct NL T 11.1 (10-12) TT 43 (31-43) Extra coag tube FVIII c 60 (50-150) VWF Antigen 41 (50-150) Ristocetin (R cof.) 52 (50-150) von Willebrand Disease Treatment DDAV (desmopressin) intranasal or IV Most Type 1 respond, some Type 2, no Type 3 Contraindicated in Type 2B Factor VIII concentrates which include VWF may be needed in some cases Inherited Defects of Coagulation Factors 12

13 CAA 2015 Annual Conference Coagulation Testing (oversimplified) att XII Fibrinogen XI IX VIII VII X V rothrombin Thrombin XIII T Fibrin Clot (not tested by T/TT) Thromboelastograph (TEG) T & TT measures clot initiation 90% of clot dynamics occur after clot initiation Coagulation Testing (oversimplified) Normal T with abnormal TT isolates the problem to these four factors att XII XI IX T VIII VII X V rothrombin Thrombin Fibrinogen Fibrin clot 13

14 CAA 2015 Annual Conference Queen Victoria Hemophilias Classic hemophilia A Factor VIII deficiency Hemophilia B Factor IX deficiency Christmas disease 14

15 CAA 2015 Annual Conference Hemophilia Severity Circulating FVIII or FIX level Normal = % Severe < 1 % Moderate 1-5 % Mild 6-50 % 15

16 CAA 2015 Annual Conference 16

17 CAA 2015 Annual Conference 17

18 CAA 2015 Annual Conference 18

19 CAA 2015 Annual Conference Hemophilia Treatment revent bleeding! Consider prophylactic FVIII or IX (2-3 x wk) Treat bleeding early - replace the missing factor VIII or IX (given IV) Monitor for complications such as orthopedic, viral and inhibitors 19

20 CAA 2015 Annual Conference Hemophilia rophylaxis IV rophylaxis given 2 to 3 times a week can prevent most bleeding episodes Regimen based mostly on half-life Hemophilia Treatment Donor derived factor concentrates in the 70 s and 80 s led to viral complications HBV, HCV, HIV MMWR July 16, 1982 Epidemiologic Notes and Reports neumocystis carinii neumonia among ersons with Hemophilia A Hemophilia Treatment Safer plasma derived concentrates are now used Newer products using recombinant technology New products with a longer half-life DDAV used in mild hemophilia A 20

21 CAA 2015 Annual Conference A Recombinant Technology Mammalian cells are provided with genetic information to produce a target protein. Cell lines may include CHO, BHK, HEK Mammalian CELLS produce a protein rotein is purified Lyophilized product Hemophilia Inhibitors Antibodies inhibitors develop in ~ 20% of persons with severe hemophilia A Antibodies neutralize the infused coagulation factor May require an activated concentrate to control bleeding Coagulation Testing (oversimplified) Normal TT with abnormal T isolates the problem to factor VII att XII XI IX T VIII VII X V rothrombin Thrombin Fibrinogen Fibrin clot 21

22 CAA 2015 Annual Conference Coag Factor Deficiencies Factor VII deficiency Autosomal Rare 1:500,000 Bleeding variable Bleeding does not correlate with level Treat with rfviia Factor XI deficiency Autosomal Rare > 1:100,000 Ashkenazi Jews (8%) Bleeding variable Treat with FF or rviia (No FXI available) Factor Deficiencies Factor XII deficiency Autosomal Rare rolongs the TT but does not result in clinical bleeding Surgery is OK Factor XIII deficiency Autosomal Rare T / TT normal Excess bleeding from umbilical stump Federal Regional Hemostasis & Thrombosis Centers (HTCs) (Hemophilia Treatment Centers) 22

23 CAA 2015 Annual Conference Captain Morgan, The Rescue Dog 23

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated) Common Inherited Coagulation Disorders Bob Miller, A 2017 Inherited Coagulation Disorders Brief review of coagulation Disorders related to platelet dysfunction (not the acquired thrombocytopenias) Disorders

More information

The Coagulation Workup In The Office Setting

The Coagulation Workup In The Office Setting CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA

More information

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis 1 Nadanotes.com 2 Nadanotes.com 3 Nadanotes.com Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis Clotting

More information

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Primary & Secondary Hemostasis Disorders http://.columbia.edu/itc/hs/medical/selective/advclinicalpathology/2004/lecture/lab%20diagnosis%20of%20bleeding%20disorders.ppt

More information

Evaluation of the Bleeding Patient

Evaluation of the Bleeding Patient Evaluation of the Bleeding Patient Screening Tests Rong He, MD Special Coagulation Laboratory, Division of Hematopathology 2015 MFMER slide-1 DISCLOSURE Relevant Financial Relationship(s) None 2015 MFMER

More information

Prior Authorization Criteria Hemophilia/Blood Factor Products

Prior Authorization Criteria Hemophilia/Blood Factor Products Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness

More information

Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1

Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1 Review of Bleeding Disorders Case 1 Robert I. Handin, MD Professor of Medicine, Harvard Medical School Hematology Division Brigham & Women s Hospital 20 year college student is home on spring break and

More information

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury. BLOOD COAGULATION The ability of the body to control the flow of blood following vascular injury is paramount to continued survival. The process of blood clotting and then the subsequent dissolution of

More information

LABORATORY APPROCH TO THE BLEEDING PATIENT

LABORATORY APPROCH TO THE BLEEDING PATIENT Anne Winkler, MD Emory University School of Medicine, Atlanta Georgia Assistant Professor, Pathology & Laboratory Medicine Medical Director, Transfusion Service, Grady Health System Assistant Director,

More information

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency

More information

OVERVIEW OF LABORATORY DIAGNOSTIC TESTING FOR PLATELET DISORDERS

OVERVIEW OF LABORATORY DIAGNOSTIC TESTING FOR PLATELET DISORDERS OVERVIEW OF LABORATORY DIAGNOSTIC TESTING FOR PLATELET DISORDERS Catherine P. M. Hayward, MD PhD, FRCP(C) Head, Coagulation, Hamilton Regional Laboratory Medicine Program Professor, Pathology and Molecular

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018 Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested

More information

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help

More information

Clotting Disorder Therapy

Clotting Disorder Therapy Last Review Date: October 13, 2017 Number: MG.MM.PH.25b Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining

More information

General Principles of. Hemostasis. Kristine Krafts, M.D.

General Principles of. Hemostasis. Kristine Krafts, M.D. General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets

More information

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone #

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone # Hemophilia Product Prior Authorization Form Please complete this form in its entirety and provide relevant progress notes and/or bleeding diaries and fax to 1-888-656-0841 or call 1-800-424-7892. All lab

More information

Glanzmann Thrombasthenia in Saudi Arabia. Prof. Layla A. M. Bashawri Imam Abdulrahman Bin Faisal University

Glanzmann Thrombasthenia in Saudi Arabia. Prof. Layla A. M. Bashawri Imam Abdulrahman Bin Faisal University Glanzmann Thrombasthenia in Saudi Arabia Prof. Layla A. M. Bashawri Imam Abdulrahman Bin Faisal University INTRODUCTION Named after the Swiss Pediatrician Eduardo Glanzmann in 1918 who described bleeding

More information

AUSTRALIAN BLEEDING DISORDERS REGISTRY

AUSTRALIAN BLEEDING DISORDERS REGISTRY AUSTRALIAN BLEEDING DISORDERS REGISTRY Annual Report 2013-14 With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (NovoSeven RT) Reference Number: CP.PHAR.220 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

CLOTTING FACTOR REPLACEMENT THERAPY

CLOTTING FACTOR REPLACEMENT THERAPY CLOTTING FACTOR REPLACEMENT THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

Thriving Amid The Turbulent Ride

Thriving Amid The Turbulent Ride Thursday, April 3 7:00 8:45 AM Rosen Shingle Creek Panzacola F 1/2 A Symposium Held in Conjunction with the 2014 NHIA Annual Conference & Exposition 2014 NHIA Annual Conference & Exposition Thriving Amid

More information

Personal history of excessive mucocutaneous bleeding. Family history of excessive bleeding. Laboratory tests of hemostasis consistent with VWD

Personal history of excessive mucocutaneous bleeding. Family history of excessive bleeding. Laboratory tests of hemostasis consistent with VWD Diagnostic Approach Personal history of excessive mucocutaneous bleeding Family history of excessive bleeding Laboratory tests of hemostasis consistent with VWD Nose Bleeds Skin Bruising Gum Bleeding Menorrhagia

More information

Basic coagulation applications and case studies

Basic coagulation applications and case studies Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases

More information

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016 Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be

More information

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of

More information

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS UnitedHealthcare Commercial Medical Benefit Drug Policy CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS Policy Number: 2018D0047K Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...

More information

Principles of Coagulation Testing. Andy Nguyen, MD 8/4/2010

Principles of Coagulation Testing. Andy Nguyen, MD 8/4/2010 Principles of Coagulation Testing Andy Nguyen, MD 8/4/2010 FSP and D-Dimer FDP vs. D-DIMER Fibrin is formed as the end result of coagulation cascade activation Fibrinolysis causes cleavage of fibrinogen,

More information

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Coagulation Cascade XII XIIa XI HMWK/Prekallikrein XIa VII Injury IX X IXa VIII Xa X TF TF/VIIa Prothrombin

More information

Perspectives on Platelet Functional Disorders in 2007

Perspectives on Platelet Functional Disorders in 2007 latelet Functional Disorders and Testing Catherine. M. Hayward, MD hd rofessor, athology & Molecular Medicine McMaster University, Hamilton, Ontario, Canada Head, Coagulation Hamilton Regional Laboratory

More information

Sysmex Educational Enhancement and Development No

Sysmex Educational Enhancement and Development No SEED Coagulation Sysmex Educational Enhancement and Development No 1 2016 Assessing platelet function a basic introduction The purpose of this newsletter is to provide a basic overview of platelet function

More information

DOWNLOAD : STATISTICS OF HEMOPHILIA

DOWNLOAD : STATISTICS OF HEMOPHILIA DOWNLOAD : STATISTICS OF HEMOPHILIA DATA & STATISTICS HEMOPHILIA NCBDDD CDC hemophilia is an inherited bleeding disorder in which the blood does not clot properly. the mission of cdcâ s division of blood

More information

A Review of Coagulation Factor Disorders

A Review of Coagulation Factor Disorders A Review of Coagulation Factor Disorders By Amy Ehlers, BS, PharmD, BCPS Until better treatments or a cure can be found, coagulation factor replacement therapies continue to improve the long-term outcome

More information

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 International Society Laboratory Hematology Milan, 12-14 May 2016 Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 Augusto B. FEDERICI Hematology and Transfusion Medicine

More information

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117 www.cap.org Coagulation Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Serviced (CMS). Coagulation Limited CGL, CGDF Analyte CGL CGDF New

More information

Hematology Emergencies: Problems with Platelets

Hematology Emergencies: Problems with Platelets Hematology Emergencies: Problems with Platelets Christian Cable, MD, FACP Associate Professor of Medicine Division of Hematology & Oncology Texas A&M HSC College of Medicine Scott & White Healthcare Fundamentals

More information

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia Corporate News Baxter International Inc. One Baxter Parkway Deerfield, IL 60015 BAXTER MEDIA CONTACT: BAXTER INVESTOR RELATIONS: Marie Kennedy Mary Kay Ladone (805) 372-3543 (847) 948-3371 Doreen Eaton

More information

Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s

Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding

More information

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS UnitedHealthcare Commercial Medical Benefit Drug Policy CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS Policy Number: PHA027 Effective Date: November 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...

More information

How to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course

How to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course How to Approach a Patient with Bleeding Nigel Key MB ChB FRCP November 1, 2016 Disclosures for Nigel Key In compliance with COI policy, ISTH requires the following disclosures to the session audience:

More information

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Disclosures Employee of Quest Diagnostics Case focus: Importance of knowing test limitation/interpretations

More information

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of

More information

A. National Hemophilia Organization

A. National Hemophilia Organization A. National Hemophilia Organization Organization name City Country Czech Society of Hemophilia Prague Czech Republic Phone +420777078509 E-mail This form completed by: info@hemofilici.cz First name Vladimír

More information

Congenital Fibrinogen Deficiency. Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1

Congenital Fibrinogen Deficiency. Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1 Congenital Fibrinogen Deficiency Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1 claude.negrier@chu-lyon.fr Afibrinogenaemia Clinical presentation Phenotypic and genotypic

More information

Coagulation Mechanisms Dr. Nervana Bayoumy

Coagulation Mechanisms Dr. Nervana Bayoumy Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand

More information

Sign up to receive ATOTW weekly -

Sign up to receive ATOTW weekly - BLOOD PHYSIOLOGY PART 2 ANAESTHESIA TUTORIAL OF THE WEEK 231 11 TH JULY 2011 Dr Karen Hayes Royal Devon & Exeter Correspondence to: kmhayes@hotmail.co.uk QUESTIONS Before continuing, try to answer the

More information

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:

More information

CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS

CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS Protocol: PHA027 Effective Date: February 1, 2019 Table of Contents Page BENEFIT CONSIDERATIONS... 1 COVERAGE RATIONALE... 2 US FOOD AND DRUG

More information

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis Haemostasis Haemostasis The function of haemostasis is: to prevent blood loss from injured vessels to stop bleeding to prevent thrombosis Haemostasis blood endothelium basement membrane subendothelium

More information

Hemostasis. by Mohie-Aldien Elsayed

Hemostasis. by Mohie-Aldien Elsayed Hemostasis by Mohie-Aldien Elsayed Hemostasis Hemostasis is defined as the process that maintains the flowing blood in a fluid state and confined to the circulatory system Coagulation prevents excess blood

More information

Blood Product Utilization

Blood Product Utilization Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary

More information

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular

More information

Category Storage Shelf Life Additional Criteria

Category Storage Shelf Life Additional Criteria CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.

More information

Physiology Unit 3 HEMATOLOGY

Physiology Unit 3 HEMATOLOGY Physiology Unit 3 HEMATOLOGY In Physiology Today Hematocrit Percentage of blood volume that is erythrocytes 45% in men 42% in women Average blood volume in is 5 L Plasma Large amounts of organic/inorganic

More information

Registry for haemophiliacs in France : FranceCoag Network. Thierry Lambert, MD

Registry for haemophiliacs in France : FranceCoag Network. Thierry Lambert, MD Registry for haemophiliacs in France : FranceCoag Network Thierry Lambert, MD Haemophilia Treatment Center,, Bicêtre History Before 1994: nothing 1994: set up of "Suivi" thérapeutique National des Hémophiles"

More information

IMPORTANCE OF COAGLUOPATHIES IN COMPANION ANIMALS

IMPORTANCE OF COAGLUOPATHIES IN COMPANION ANIMALS 74 IMPORTANCE OF COAGLUOPATHIES IN COMPANION ANIMALS Urs Giger School of Veterinary Medicine, University of Pennsylvania, Philadelphia, USA Practical Tools to Approach Bleeding Patients Urs Giger, Dipl.

More information

Coagulopathy Case-2. Andy Nguyen, M.D. 2009

Coagulopathy Case-2. Andy Nguyen, M.D. 2009 Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious

More information

Haemostasis Reagents product list 2018

Haemostasis Reagents product list 2018 Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch Product # ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 Product name

More information

J. Martin Johnston, MD. Pediatric Project ECHO 7 December 2018

J. Martin Johnston, MD. Pediatric Project ECHO 7 December 2018 J. Martin Johnston, MD Pediatric Project ECHO 7 December 2018 Objectives Review history and physical exam as they relate to a potential bleeding disorder Discuss step-wise laboratory evaluation: screening

More information

4/5/2017. Molecular Testing Applications in Coagulation. Disclosures. Objectives. Human Genome Chromosome Analysis.

4/5/2017. Molecular Testing Applications in Coagulation. Disclosures. Objectives. Human Genome Chromosome Analysis. Disclosures Relevant Financial Relationship(s): NONE Molecular Testing Applications in Coagulation Off Label Usage: NONE Sara Lassila, MB(ASCP) CM Clinical Laboratory Scientists of Alaska April 6 th, 2017

More information

Clumsy Coagulation Communication

Clumsy Coagulation Communication Clumsy Coagulation Communication Let s Blame the Lab! Lab Clinician Communication Barriers and opportunities Where are the errors made? How do we enhance patient experience? George A Fritsma MS, MLS, Your

More information

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask

More information

Clinical Use of Plasma for Transfusion. Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School

Clinical Use of Plasma for Transfusion. Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School Clinical Use of Plasma for Transfusion Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School PLASMA PRODUCTS FOR TRANSFUSION Fresh Frozen Plasma (FFP) Thawed Plasma

More information

Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

Ch 13: Blood. What does blood do? Transport: Regulation: Protection: Ch 13: Blood What does blood do? Transport: Regulation: Protection: SLOs Describe the composition of plasma and list the major functions of plasma proteins. Map hematopoiesis, starting from a pluripotent

More information

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17 Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108 A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, 111 115 Acquired platelet disorders, 99 108 ACT. See Activated clotting time (ACT) Activated

More information

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D. Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin

More information

Coagulation in perspective: Blood management. Objectives

Coagulation in perspective: Blood management. Objectives Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.

More information

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health

More information

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary

More information

Clotting Factors and Coagulant Blood Products

Clotting Factors and Coagulant Blood Products Clotting Factors and Coagulant Blood Products Policy Number: 5.02.520 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

Molecular diagnosis of haemophilia and other bleeding disorders

Molecular diagnosis of haemophilia and other bleeding disorders Molecular diagnosis of haemophilia and other bleeding disorders Jayandharan G Rao Associate Professor Department of Haematology Christian Medical College Vellore, India. Jayandharan et al, J Genet Synd

More information

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection.

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. Biostate Malaysia NAME OF THE MEDICINE Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. DESCRIPTION Biostate is a high purity, sterile, powder for injection

More information

Background, Development and Clinical Use of rfviia. Slovenian Hematology Society April 17, 2015

Background, Development and Clinical Use of rfviia. Slovenian Hematology Society April 17, 2015 Background, Development and Clinical Use of rfviia. Slovenian Hematology Society April 17, 2015 Ulla Hedner MD PhD Prof. em. University of Lund, Sweden. Key Issues in Hemophilia Treatment All bleedings

More information

Current laboratory practices in the diagnosis and management of haemophilia

Current laboratory practices in the diagnosis and management of haemophilia Current laboratory practices in the diagnosis and management of haemophilia Marc Jacquemin University of Leuven BSTH 2013 Detection of severe haemophilia A Validation of the FVIII assay for the detection

More information

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection.

Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. Biostate Singapore NAME OF THE MEDICINE Human coagulation factor VIII and human von Willebrand factor complex, powder for injection. DESCRIPTION Biostate is a high purity, sterile, powder for injection

More information

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare

More information

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis

More information

Disclosures. Agenda 2/3/2011. Current Options and New Developments in Hemophilia. Research support to OHSU from:

Disclosures. Agenda 2/3/2011. Current Options and New Developments in Hemophilia. Research support to OHSU from: Current Options and New Developments in Hemophilia Michael Recht, MD, PhD Director, The Hemophilia Center Oregon Health and Science University Disclosures Research support to OHSU from: Baxter Pfizer NovoNordisk

More information

Subject: Clotting Factors and Coagulant Blood Products

Subject: Clotting Factors and Coagulant Blood Products 09-J0000-34 Original Effective Date: 03/15/01 Reviewed: 04/11/18 Revised: 03/15/19 Subject: Clotting Factors and Coagulant Blood Products THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

Ph. D THESIS EVALUATION OF A GLOBAL PLATELET FUNCTION TEST (PFA-100 CLOSURE TIME) IN DIAGNOSTICS OF PLATELET FUNCTION DISORDERS

Ph. D THESIS EVALUATION OF A GLOBAL PLATELET FUNCTION TEST (PFA-100 CLOSURE TIME) IN DIAGNOSTICS OF PLATELET FUNCTION DISORDERS Ph. D THESIS EVALUATION OF A GLOBAL PLATELET FUNCTION TEST (PFA-100 CLOSURE TIME) IN DIAGNOSTICS OF PLATELET FUNCTION DISORDERS ADRIENNE KERÉNYI M.D. UNIVERSITY OF DEBRECEN, MEDICAL AND HEALTH SCIENCE

More information

Current and Emerging Treatment Paradigms in the Management of Hemophilia

Current and Emerging Treatment Paradigms in the Management of Hemophilia Current and Emerging Treatment Paradigms in the Management of Hemophilia Barbara A. Konkle, MD Associate Director, Washington Center for Bleeding Disorders Director, Clinical and Translational Research

More information

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia

More information

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Personalized hemophilia treatment Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Evolution of Hemophilia

More information

PRINCIPLES OF CLOTTING FACTOR THERAPY IN HEMOPHILIA A and B

PRINCIPLES OF CLOTTING FACTOR THERAPY IN HEMOPHILIA A and B PRINCIPLES OF CLOTTING FACTOR THERAPY IN HEMOPHILIA A and B 2013 Carol K. Kasper, M.D. Hemophilia Treatment Center Los Angeles Orthopaedic Hospital 2400 South Flower Street Los Angeles, CA 90007 carolkasper@hotmail.com

More information

Flow Cytometric Evaluation of Platelet Disorders

Flow Cytometric Evaluation of Platelet Disorders Flow Cytometric Evaluation of Platelet Disorders Dong Chen MD PhD Special Coagulation Laboratory Division of Hematopathology Mayo Clinic DISCLOSURE Relevant Financial Relationship(s) None Off Label Usage

More information

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK Drug Class Insight HEMOPHILIA Background, new developments, key strategies INTRODUCTION Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. 20,000 patients in the

More information

Laboratory Monitoring of Anticoagulation

Laboratory Monitoring of Anticoagulation Michael Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Learning Objectives Explain the role of common laboratory tests used in monitoring of anticoagulation therapy.

More information

Alnylam Pharmaceuticals R&D Day. July 11, 2013

Alnylam Pharmaceuticals R&D Day. July 11, 2013 Alnylam Pharmaceuticals R&D Day July 11, 2013 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and

More information

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,

More information

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary

More information

Factor Replacement Products. Hem/Onc Fellows 2017

Factor Replacement Products. Hem/Onc Fellows 2017 Factor Replacement Products Hem/Onc Fellows 2017 Factor VIII concentrates: History and Current Issues 1950-1960 Fresh Frozen Plasma Mid 1960 Cryoprecipitate from FFP 1970s Lyophilized concentrates from

More information

Use of ROTEM from the Laboratory Perspective. A/Prof David Roxby SA Pathology

Use of ROTEM from the Laboratory Perspective. A/Prof David Roxby SA Pathology Use of ROTEM from the Laboratory Perspective A/Prof David Roxby SA Pathology What s the Problem? Constant changes in treatment recommendations Lack of good evidence to guide practice Variations in clinical

More information

Von Willebrand Disease: Elucidating the Clinical Picture Through the Use of Molecular Methods

Von Willebrand Disease: Elucidating the Clinical Picture Through the Use of Molecular Methods Von Willebrand Disease: Elucidating the Clinical Picture Through the Use of Molecular Methods Elisa B. Cardenas, MS, MT(ASCP), Owatha L. Tatum, PhD, MP(ASCP) (Molecular Pathology, School of Allied Health

More information

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~ Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~ Computer and Information Division, RIKEN Hiroki Iwata Supramolecular Science Laboratory,

More information

Management of Hemophilia under Limited Resources

Management of Hemophilia under Limited Resources Management of Hemophilia under Limited Resources Ampaiwan Chuansumrit, M.D. ISTH Advanced Training Course International Hemophilia Training Center-Bangkok Faculty of Medicine Ramathibodi Hospital, Mahidol

More information

Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015

Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates

More information

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3. Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.1; 14 Apr 2016) VI.2 VI.2.1 Elements for a Public Summary Overview of

More information

New Anticoagulants Linda Liu, M.D.

New Anticoagulants Linda Liu, M.D. Difficult Task New Anticoagulants Professor UCSF Dept of Anesthesia 15 minutes! Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban Relation to anesthesia Rapid reversal Regional anesthesia UC

More information